Point72 DIFC Ltd Invests $32,000 in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Point72 DIFC Ltd bought a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the second quarter, HoldingsChannel.com reports. The fund bought 6,010 shares of the company’s stock, valued at approximately $32,000.

Other institutional investors have also recently modified their holdings of the company. Rinkey Investments purchased a new stake in shares of ClearPoint Neuro in the second quarter worth $307,000. Price T Rowe Associates Inc. MD grew its stake in shares of ClearPoint Neuro by 7.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company’s stock worth $170,000 after acquiring an additional 1,813 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of ClearPoint Neuro by 23,048.0% in the first quarter. Russell Investments Group Ltd. now owns 46,296 shares of the company’s stock worth $315,000 after acquiring an additional 46,096 shares during the last quarter. Legato Capital Management LLC grew its stake in shares of ClearPoint Neuro by 21.6% in the second quarter. Legato Capital Management LLC now owns 158,968 shares of the company’s stock worth $857,000 after acquiring an additional 28,227 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of ClearPoint Neuro by 202.2% in the second quarter. Marshall Wace LLP now owns 58,260 shares of the company’s stock worth $314,000 after acquiring an additional 38,984 shares during the last quarter. 30.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on CLPT shares. B. Riley started coverage on ClearPoint Neuro in a report on Thursday, July 25th. They set a “buy” rating and a $10.00 price target on the stock. Lake Street Capital increased their target price on ClearPoint Neuro from $11.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, August 27th.

ClearPoint Neuro Trading Up 0.7 %

NASDAQ:CLPT opened at $11.19 on Monday. ClearPoint Neuro, Inc. has a 12-month low of $4.05 and a 12-month high of $13.47. The stock has a 50-day moving average price of $10.44 and a 200 day moving average price of $7.59. The stock has a market capitalization of $306.83 million, a P/E ratio of -13.32 and a beta of 1.12.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The business had revenue of $7.86 million during the quarter, compared to analysts’ expectations of $7.50 million. ClearPoint Neuro had a negative return on equity of 64.23% and a negative net margin of 64.06%. During the same quarter last year, the business posted ($0.29) EPS. On average, research analysts predict that ClearPoint Neuro, Inc. will post -0.65 earnings per share for the current fiscal year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.